SCHEMBL23960356

SCHEMBL23960356

CC1(I)CN=C(c2ccc(F)cc2)O1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.35
LIPG Q9Y5X9 1/20 0.35
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
DGAT1 O75907 1/20 0.33
CYP2D6 P10635 1/20 0.32
NPY5R Q15761 3/20 0.32
ALOX15 P16050 1/20 0.32
USP1 O94782 1/20 0.32
WDR48 Q8TAF3 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
PABPC1 P11940 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20410835 0.66 ROCK1 (0.35)
SCHEMBL15054324 0.62 LMNA (0.36) NPC1RAB9ANPY5RLMNASMN1; SMN2
SCHEMBL5464687 0.61 NPC1 (0.43) NPC1RAB9ASMN1; SMN2NOTUM
SCHEMBL2317085 0.60 ALDH1A1 (0.36) LPLLIPGNPC1RAB9ADGAT1
SCHEMBL29048472 0.60 MAPK14 (0.37) LPLLIPGNPC1RAB9ANPY5R
SCHEMBL17512909 0.58 USP1 (0.37) NPC1RAB9AUSP1WDR48LMNA
SCHEMBL29839923 0.58 NPC1 (0.40) NPC1RAB9AALOX15USP1WDR48
SCHEMBL7913803 0.57 ENPP2 (0.43) NPC1RAB9AALOX15USP1WDR48
SCHEMBL7911822 0.57 ENPP2 (0.43) NPC1RAB9AALOX15USP1WDR48
SCHEMBL19072298 0.57 NPC1 (0.42) NPC1RAB9ASMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295096-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES INC (US) 2023-09-21 US disclosed
WO-2021216661-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
WO-2021216660-A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
WO-2021216656-A1 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed
WO-2021216642-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295096-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV HCCS, HAVCR2, MAVS LPL 3227/4885LIPG 3792/4885NPC1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.